Iron(II) Is a Modulator of Ryanodine-Sensitive Calcium Channels of Cardiac Muscle Sarcoplasmic Reticulum

E. Kim, S. N. Giri, Isaac N Pessah

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Iron is examined for its ability to modify Ca2+ transport across sarcoplasmic reticulum (SR) and to alter the binding of [3H]ryanodine to its high-affinity site on the Ca2+ release channel complex of SR preparations from rat heart. Iron(III) (added as ferric chloride) has negligible activity on active Ca2+ accumulation into SR and on the binding of [3H]ryanodine. In contrast, Fe(II) (added as ferrous sulfate) is a potent inhibitor of both Ca2+-induced Ca2+ release (IC50 of 29 μM) and DXR-induced Ca2+ release (IC50 of 14 μM). Iron(II) enhances the rate of active Ca2+ uptake into SR vesicles, mimicking the actions of the known SR Ca2+ channel blocker ruthenium red. The underlying mechanism of Fe(II) on SR Ca2+ transport is shown to be a direct and potent action on the ryanodine receptor. Fe(II) inhibits the binding of [3H]ryanodine when assayed in the presence of 5 μM Ca2+ with an IC50 of 4 μM and in an apparently cooperative manner (nH = 1.7). In the presence of physiological (1 mM) Mg2+ Fe(II) decreases the sensitivity of ryanodine receptors toward activation by Ca2+ shifting EC50 from 18 to 35 μM in the absence and presence of 5 μM Fe(II), respectively, without significant decrease in maximum [3H]ryanodine occupancy. In the presence of 5 μM Ca2+ and 1 mM Mg2+, Fe(II) decreases the potency of doxorubicin (DXR) on [3H]ryanodine binding (shifts EC50 from 8 to 24 μM in the absence and presence of 5 μM Fe(II)). These results suggest that Fe(II) competes with Ca2+ at the activator sites on the channel complex. The actions of Fe(II) on ryanodine receptor function is not correlated with membrane lipid peroxidation of SR vesicles since Fe(II) does not produce detectable changes in malondialdehyde using the thiobarbituric acid assay. These results demonstrate a direct inhibition of the Ca2+ release channel of cardiac SR by Fe(II) which may be important in pathological states of the heart during iron overload.

Original languageEnglish (US)
Pages (from-to)57-66
Number of pages10
JournalToxicology and Applied Pharmacology
Volume130
Issue number1
DOIs
StatePublished - Jan 1995

Fingerprint

Ryanodine
Sarcoplasmic Reticulum
Calcium Channels
Modulators
Muscle
Myocardium
Iron
Ryanodine Receptor Calcium Release Channel
ferrous sulfate
Doxorubicin
Inhibitory Concentration 50
Ruthenium Red
Membrane Lipids
Malondialdehyde
Rats
Assays
Chemical activation
Iron Overload
Lipid Peroxidation

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Iron(II) Is a Modulator of Ryanodine-Sensitive Calcium Channels of Cardiac Muscle Sarcoplasmic Reticulum. / Kim, E.; Giri, S. N.; Pessah, Isaac N.

In: Toxicology and Applied Pharmacology, Vol. 130, No. 1, 01.1995, p. 57-66.

Research output: Contribution to journalArticle

@article{2daf409a139c454883517decf0e09da2,
title = "Iron(II) Is a Modulator of Ryanodine-Sensitive Calcium Channels of Cardiac Muscle Sarcoplasmic Reticulum",
abstract = "Iron is examined for its ability to modify Ca2+ transport across sarcoplasmic reticulum (SR) and to alter the binding of [3H]ryanodine to its high-affinity site on the Ca2+ release channel complex of SR preparations from rat heart. Iron(III) (added as ferric chloride) has negligible activity on active Ca2+ accumulation into SR and on the binding of [3H]ryanodine. In contrast, Fe(II) (added as ferrous sulfate) is a potent inhibitor of both Ca2+-induced Ca2+ release (IC50 of 29 μM) and DXR-induced Ca2+ release (IC50 of 14 μM). Iron(II) enhances the rate of active Ca2+ uptake into SR vesicles, mimicking the actions of the known SR Ca2+ channel blocker ruthenium red. The underlying mechanism of Fe(II) on SR Ca2+ transport is shown to be a direct and potent action on the ryanodine receptor. Fe(II) inhibits the binding of [3H]ryanodine when assayed in the presence of 5 μM Ca2+ with an IC50 of 4 μM and in an apparently cooperative manner (nH = 1.7). In the presence of physiological (1 mM) Mg2+ Fe(II) decreases the sensitivity of ryanodine receptors toward activation by Ca2+ shifting EC50 from 18 to 35 μM in the absence and presence of 5 μM Fe(II), respectively, without significant decrease in maximum [3H]ryanodine occupancy. In the presence of 5 μM Ca2+ and 1 mM Mg2+, Fe(II) decreases the potency of doxorubicin (DXR) on [3H]ryanodine binding (shifts EC50 from 8 to 24 μM in the absence and presence of 5 μM Fe(II)). These results suggest that Fe(II) competes with Ca2+ at the activator sites on the channel complex. The actions of Fe(II) on ryanodine receptor function is not correlated with membrane lipid peroxidation of SR vesicles since Fe(II) does not produce detectable changes in malondialdehyde using the thiobarbituric acid assay. These results demonstrate a direct inhibition of the Ca2+ release channel of cardiac SR by Fe(II) which may be important in pathological states of the heart during iron overload.",
author = "E. Kim and Giri, {S. N.} and Pessah, {Isaac N}",
year = "1995",
month = "1",
doi = "10.1006/taap.1995.1008",
language = "English (US)",
volume = "130",
pages = "57--66",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Iron(II) Is a Modulator of Ryanodine-Sensitive Calcium Channels of Cardiac Muscle Sarcoplasmic Reticulum

AU - Kim, E.

AU - Giri, S. N.

AU - Pessah, Isaac N

PY - 1995/1

Y1 - 1995/1

N2 - Iron is examined for its ability to modify Ca2+ transport across sarcoplasmic reticulum (SR) and to alter the binding of [3H]ryanodine to its high-affinity site on the Ca2+ release channel complex of SR preparations from rat heart. Iron(III) (added as ferric chloride) has negligible activity on active Ca2+ accumulation into SR and on the binding of [3H]ryanodine. In contrast, Fe(II) (added as ferrous sulfate) is a potent inhibitor of both Ca2+-induced Ca2+ release (IC50 of 29 μM) and DXR-induced Ca2+ release (IC50 of 14 μM). Iron(II) enhances the rate of active Ca2+ uptake into SR vesicles, mimicking the actions of the known SR Ca2+ channel blocker ruthenium red. The underlying mechanism of Fe(II) on SR Ca2+ transport is shown to be a direct and potent action on the ryanodine receptor. Fe(II) inhibits the binding of [3H]ryanodine when assayed in the presence of 5 μM Ca2+ with an IC50 of 4 μM and in an apparently cooperative manner (nH = 1.7). In the presence of physiological (1 mM) Mg2+ Fe(II) decreases the sensitivity of ryanodine receptors toward activation by Ca2+ shifting EC50 from 18 to 35 μM in the absence and presence of 5 μM Fe(II), respectively, without significant decrease in maximum [3H]ryanodine occupancy. In the presence of 5 μM Ca2+ and 1 mM Mg2+, Fe(II) decreases the potency of doxorubicin (DXR) on [3H]ryanodine binding (shifts EC50 from 8 to 24 μM in the absence and presence of 5 μM Fe(II)). These results suggest that Fe(II) competes with Ca2+ at the activator sites on the channel complex. The actions of Fe(II) on ryanodine receptor function is not correlated with membrane lipid peroxidation of SR vesicles since Fe(II) does not produce detectable changes in malondialdehyde using the thiobarbituric acid assay. These results demonstrate a direct inhibition of the Ca2+ release channel of cardiac SR by Fe(II) which may be important in pathological states of the heart during iron overload.

AB - Iron is examined for its ability to modify Ca2+ transport across sarcoplasmic reticulum (SR) and to alter the binding of [3H]ryanodine to its high-affinity site on the Ca2+ release channel complex of SR preparations from rat heart. Iron(III) (added as ferric chloride) has negligible activity on active Ca2+ accumulation into SR and on the binding of [3H]ryanodine. In contrast, Fe(II) (added as ferrous sulfate) is a potent inhibitor of both Ca2+-induced Ca2+ release (IC50 of 29 μM) and DXR-induced Ca2+ release (IC50 of 14 μM). Iron(II) enhances the rate of active Ca2+ uptake into SR vesicles, mimicking the actions of the known SR Ca2+ channel blocker ruthenium red. The underlying mechanism of Fe(II) on SR Ca2+ transport is shown to be a direct and potent action on the ryanodine receptor. Fe(II) inhibits the binding of [3H]ryanodine when assayed in the presence of 5 μM Ca2+ with an IC50 of 4 μM and in an apparently cooperative manner (nH = 1.7). In the presence of physiological (1 mM) Mg2+ Fe(II) decreases the sensitivity of ryanodine receptors toward activation by Ca2+ shifting EC50 from 18 to 35 μM in the absence and presence of 5 μM Fe(II), respectively, without significant decrease in maximum [3H]ryanodine occupancy. In the presence of 5 μM Ca2+ and 1 mM Mg2+, Fe(II) decreases the potency of doxorubicin (DXR) on [3H]ryanodine binding (shifts EC50 from 8 to 24 μM in the absence and presence of 5 μM Fe(II)). These results suggest that Fe(II) competes with Ca2+ at the activator sites on the channel complex. The actions of Fe(II) on ryanodine receptor function is not correlated with membrane lipid peroxidation of SR vesicles since Fe(II) does not produce detectable changes in malondialdehyde using the thiobarbituric acid assay. These results demonstrate a direct inhibition of the Ca2+ release channel of cardiac SR by Fe(II) which may be important in pathological states of the heart during iron overload.

UR - http://www.scopus.com/inward/record.url?scp=0028817709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028817709&partnerID=8YFLogxK

U2 - 10.1006/taap.1995.1008

DO - 10.1006/taap.1995.1008

M3 - Article

C2 - 7530865

AN - SCOPUS:0028817709

VL - 130

SP - 57

EP - 66

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 1

ER -